Syntropic Medical

Problem: Over 280 million people globally suffer from depression, yet 53% experience no benefit from medication, 25% discontinue due to side effects, and more than 50% face relapse. Current solutions are not good enough and fail to target the root cause of the disease. Solution: Syntropic uses flickering light stimulation to activate the brain's resident immune cells and instruct them to open a restrictive coating that surrounds the neurons. This promotes the formation of new synaptic connections and results in a strong improvement in depressive symptoms without side effects. Target Markets: Hospitals, Clinics, Mental Health Centers. Looking for business opportunities in: Technical Expertise, Business Expertise, Other (IP, Legal, Financial), Market Access, Investor Technology Readiness Level: TRL 5 Prototype Contact info: Mark Caffrey mark@syntropicmedical.com